Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar Magnesium for NAFLD in People Living with HIV
NCT05211284Phase 2Terminated
- Sponsor
- Zydus Therapeutics
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of saroglitazar in non-alcoholic fatty liver disease (NAFLD), sponsored by Zydus Therapeutics. Primary endpoint: Change in Hepatic Fat Content Measured by MRI Proton Density Fat Fraction (MRI PDFF) at Week 24. Started Dec 2022; status: terminated.
02
Drugs
saroglitazar
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05211284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211284.